<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Felicitas</forename><surname>Strehlow</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology, Oncology and Tumour Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandra</forename><surname>Bauer</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medical Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Martus</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Institute of Clinical Epidemiology and Applied Biostatistics</orgName>
								<orgName type="institution">University Tuebingen</orgName>
								<address>
									<settlement>Tuebingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Weller</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Roth</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uwe</forename><surname>Schlegel</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Knappschaftskrankenhaus, University Hospital Bochum</orgName>
								<address>
									<settlement>Bochum</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><surname>Seidel</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Knappschaftskrankenhaus, University Hospital Bochum</orgName>
								<address>
									<settlement>Bochum</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carmen</forename><surname>Scheibenbogen</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medical Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Agnieszka</forename><surname>Korfel</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology, Oncology and Tumour Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Stephan</forename><surname>Kreher</surname></persName>
							<email>stephan.kreher@charite.de</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology, Oncology and Tumour Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Zurich Open Repository</orgName>
								<orgName type="institution">Archive University of Zurich University Library Strickhofstrasse 39</orgName>
								<address>
									<postCode>CH-8057</postCode>
									<settlement>Zurich www.zora.uzh.ch</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Zurich Open Repository and Archive</orgName>
								<orgName type="institution">University of Zurich ZORA URL</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Hematology, Oncology, and Tumour Immunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">9523C5F4EEB927A72894144FDED8807F</idno>
					<idno type="DOI">10.1007/s11060-016-2162-5</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:46+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Osteopontin</term>
					<term>cerebrospinal fluid</term>
					<term>PCNSL</term>
					<term>SCNSL</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Central nervous system lymphoma (CNSL) is diagnostically challenging.</s><s>The identification of reliable and easy to measure biomarkers is desirable to facilitate diagnosis.</s><s>Here, we evaluated the value of cerebrospinal fluid (CSF) osteopontin (OPN) as a diagnostic biomarker for CNSL.</s><s>OPN concentrations in CSF from 37 patients with CNSL (29 with primary CNSL and 8 with secondary CNS involvement of systemic lymphoma) and 36 controls [6 patients with inflammatory CNS disease other than multiple sclerosis (MS), 8 with MS, 9 with glioblastoma (GBM) and 13 healthy controls] were determined using an enzyme-linked immunosorbent assay.</s><s>Non-parametric tests and receiver operating characteristic (ROC) curves were performed for determination of diagnostic accuracy.</s><s>Median CSF OPN level in all CNSL patients was 620 ng/mL and higher than in patients with inflammatory CNS disease (356 ng/mL); P &lt; .05,</s><s>MS (163 ng/mL); P &lt; .01,</s><s>GBM (41 ng/mL); P &lt; .01,</s><s>or healthy controls (319 ng/mL); P &lt; .01.</s><s>The area under the ROC curve was 0.865 [95 % confidence interval (CI) 0.745-0.985]</s><s>for differentiating CNSL and patients with inflammatory CNS disease; 0.956 (95 % CI 0.898-1.000)</s><s>for CNSL and MS patients; 0.988 (95 % CI 0.964-1.000)</s><s>for CNSL and GBM patients, and 0.915 (95 % CI 0.834-0.996)</s><s>for CNSL patients and healthy controls.</s><s>In multivariate analysis, high CSF OPN level was associated with shorter progression-free (HR 1.61, 95 % CI 1.13-2.31;</s><s>P = .009)</s><s>and overall survival (HR 1.52, 95 % CI 1.04-2.21;</s><s>P = .029).</s><s>CSF OPN is a potential biomarker in CNSL.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Central nervous system lymphoma (CNSL) arises as primary CNS lymphoma (PCNSL) -a lymphoma that is confined to the CNS at time of diagnosis -or as secondary CNS involvement of systemic lymphoma (SCNSL) <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>.</s><s>The diagnosis is typically based on contrast-enhanced cranial magnetic resonance imaging and histopathological confirmation by a biopsy from a CNS lesion <ref type="bibr" target="#b3">[4]</ref>.</s><s>However, a biopsy may be challenging in vulnerable brain regions, and in some cases histological findings are inconclusive, particularly after steroid pre-treatment.</s><s>The utility of cerebrospinal fluid (CSF) diagnostics based on tumour cell identification such as conventional CSF cytomorphology, flow cytometry <ref type="bibr" target="#b4">[5]</ref> or monoclonality assessment by polymerase chain reaction <ref type="bibr" target="#b5">[6]</ref> is limited to cases with leptomeningeal involvement which is present in approximately 40-50% of SCNSL and in less than 20% of PCNSL <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>Identification of reliable diagnostic markers in CSF representing an easily accessible compartment is highly desirable to facilitate the diagnosis.</s></p><p><s>In the search for diagnostic and prognostic biomarkers for CNSL, microRNA expression patterns in the CSF and blood have yielded promising results <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr">[11]</ref>.</s><s>These studies, however, lacked a comparison to other brain tumours.</s><s>Sasayama et al. reported elevated interleukin-10 in CSF of PCNSL patients as compared to patients with other CNS malignancies <ref type="bibr">[12]</ref>.</s><s>Our group detected elevated CXCL13 concentration in CSF of 30 PCNSL patients as compared to patients with other CNS malignancies and non-malignant CNS diseases <ref type="bibr" target="#b11">[13]</ref>.</s><s>These findings were confirmed in an analysis of 60 PCNSL and 23 SCNSL samples <ref type="bibr" target="#b12">[14]</ref>.</s><s>Viaccoz et al. identified neopterin, a nonspecific marker of CNS inflammation, as possible marker to differentiate PCNSL from other brain tumours <ref type="bibr">[15]</ref>.</s><s>Osteopontin (OPN) is a proinflammatory cytokine and cell-matrix glycoprotein with numerous cellular functions including immune cell activation, B-cell migration and proliferation, chemotaxis, cell communication, focal adhesion, and suppression of antitumour immunity <ref type="bibr" target="#b13">[16]</ref>.</s><s>High OPN expression is associated with progression, metastatic spread, and poor prognosis in many malignancies.</s><s>Several studies in different human malignancies identified OPN as suitable diagnostic and prognostic biomarker <ref type="bibr">[17]</ref><ref type="bibr" target="#b14">[18]</ref><ref type="bibr">[19]</ref><ref type="bibr" target="#b15">[20]</ref><ref type="bibr" target="#b16">[21]</ref><ref type="bibr">[22]</ref><ref type="bibr" target="#b18">[23]</ref><ref type="bibr" target="#b19">[24]</ref>.</s><s>In PCNSL, osteopontin (also known as secreted phosphoprotein 1, SPP1) is one of the most differentially up-regulated genes as compared to both nodal and extranodal non-CNS diffuse large B-cell lymphoma (DLBCL) <ref type="bibr" target="#b20">[25]</ref><ref type="bibr">[26]</ref><ref type="bibr">[27]</ref>.</s><s>Immunohistochemical analyses of formalin-fixed, paraffin-embedded tissue previously confirmed high-level expression of OPN in PCNSL <ref type="bibr" target="#b20">[25,</ref><ref type="bibr">26,</ref><ref type="bibr" target="#b21">28]</ref>.</s><s>In this study, we evaluated the utility of OPN levels in the CSF as a diagnostic biomarker for CNSL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and samples</head><p><s>CSF samples were obtained prior to chemotherapy by lumbar puncture from 37 immunocompetent patients with CNSL: 29 with PCNSL and 8 with SCNSL.</s><s>Steroid pre-treatment was allowed.</s><s>Four control groups were analysed: (1) 6 patients with inflammatory CNS disease other than multiple sclerosis (MS), among them cerebral toxoplasmosis, cerebral sarcoidosis, and unspecified noninfectious encephalitis, (2) 8 patients with MS, (3) 9 patients with glioblastoma (GBM) and (4) 13 healthy controls, i.e. patients without CNS disease who underwent diagnostic lumbar puncture for peripheral neuropathy or headache, the latter ones to rule out meningitis or subarachnoidal bleeding; all of those showed no evidence of CNS disease in the following workup.</s></p><p><s>All CSF samples were processed immediately at room temperature by centrifugation for four minutes at 4,000 rpm.</s><s>Supernatants were collected and stored at -80°C.</s><s>Paired serum samples were collected from 17 PCNSL patients, all inflammatory CNS disease patients, and all healthy controls at the time of lumbar puncture and stored at -80°C.</s><s>CSF cell count and protein were analysed in 26 CNSL patients, all inflammatory CNS disease patients, and all healthy controls.</s><s>All patients gave written informed consent in accordance with the Declaration of Helsinki and the local Institutional Review Board-approved protocols.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Enzyme-linked immunosorbent assay</head><p><s>OPN concentrations in CSF and serum were determined using the enzyme-linked immunosorbent assay (ELISA) from R&amp;D (Quantikine ELISA Human Osteopontin Immunoassay, DOST00; R&amp;D Systems Europe, Ltd., Abingdon, UK).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Descriptive and explorative data analysis of clinical and ELISA data were performed.</s><s>Quantitative parameters were tested for normal distribution.</s><s>Distribution of patients' characteristics was analysed by the chi-square test.</s><s>The Kruskal-Wallis and Mann-Whitney U tests with adjusted P value due to Bonferroni correction were used as non-parametric tests to evaluate the quantitative parameters.</s><s>If not stated different, Bonferroni correction was applied with factor 10 (number of pairwise comparisons between 5 groups) in analyses with CNSL patients (PCNSL and SCNSL) vs. control groups.</s></p><p><s>Bonferroni correction with factor 15 (number of pairwise comparisons between 6 groups) was applied in analyses with PCNSL vs. SCNSL vs. control groups.</s><s>In OPN serum, CSF cell count, and CSF protein analyses Bonferroni correction with factor 3 (number of pairwise comparisons between 3 groups) was used.</s><s>Comparisons between CSF and serum levels in identical patients were done using the Wilcoxon signed rank test.</s><s>Receiver operating characteristic (ROC) curves were performed on levels of CSF OPN.</s><s>In these curves, for each potential cut-off value of the respective diagnostic marker the pair of sensitivity and 1-specificity is determined and plotted vs. each other.</s><s>The cut-off values themselves cannot be read from the curve.</s><s>The choice of the specific cut-off was done according to the criterion of the OPN level at which sensitivity and specificity were most alike.</s></p><p><s>Overall survival (OS) and progression-free survival (PFS) were analysed with the Kaplan-Meiermethod for PCNSL patients.</s><s>PFS was defined as the time from beginning of treatment to first progression or death from any cause.</s><s>OS was defined as the time from beginning of treatment to death.</s><s>Spearman correlations (Spearman correlation coefficient rho = r) were used to quantify the association of multifocal brain involvement (3 ordered categories) and CSF OPN level, age and CSF OPN level, CSF cell count and CSF OPN level as well as CSF protein and CSF OPN level.</s><s>To assess the prognostic value of CSF OPN in principle, simple and multiple Cox proportional hazard models were calculated ("forward" stepwise variable selection with criteria P = .10</s><s>(exclusion), P = .05</s><s>(inclusion)).</s><s>All hazard ratios (HR) refer to a change of 100 units of CSF OPN.</s></p><p><s>For statistical analyses IBM SPSS software package, release 22.0, and GraphPad Prism software package, release 6.0, were used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient characteristics</head><p><s>Clinical and histopathological characteristics of CNSL patients are summarised in Table <ref type="table">1</ref>.</s><s>Twentythree (79%) PCNSL and five (63%) SCNSL patients had steroid treatment before lumbar puncture.</s></p><p><s>An elevated (≥5/µL) CSF cell count was detected in 16 of 26 (62%) patients with CNSL (median 10.0/µL, range 1.0-14,842.0/µL);</s><s>total CSF protein was elevated (&gt;45 mg/dL) in 20 (77%) patients (median 74.0 mg/dL, range 28.0-341.0</s><s>mg/dL).</s><s>CSF cell count was elevated in one of six (17%) patients with inflammatory CNS disease (median 1.7/µL, range 0.3-9.3/µL)</s><s>and in none of 13 healthy controls (median 0.7/µL, range 0.3-2.7/µL).</s><s>Total CSF protein was elevated in 3 (50%) cases with inflammatory CNS disease (median 48.1 mg/dL, range 40.2-64.5 mg/dL) and in one (8%) of the healthy controls (median 37.5 mg/dL, range 18.4-49.5</s><s>mg/dL).</s></p><p><s>CSF cell count was higher in CNSL patients than in patients with inflammatory CNS disease; P &lt; .01 and healthy controls; P &lt; .01.</s><s>CSF protein in CNSL patients and patients with inflammatory CNS disease showed not significant difference; P = .291,</s><s>but was higher in CNSL patients than in healthy controls; P &lt; .01.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OPN levels in CNSL patients and control groups</head><p><s>CSF and serum OPN levels of CNSL patients and control groups as well as corresponding P values are shown in Figure <ref type="figure" target="#fig_0">1</ref>, 2A, and 2B.</s><s>CSF OPN levels did not differ between PCNSL (median 620 ng/mL, range 60-890 ng/mL) and SCNSL patients (median 608 ng/mL, range 153-818 ng/mL); P = 1.00.</s><s>According to the Kruskal-Wallis test there was a significant difference between the OPN CSF values in CNSL patients and all control groups; P &lt; .001.</s><s>Highest CSF OPN levels were found in PCNSL and SCNSL patients.</s></p><p><s>Patients with inflammatory CNS disease (median 356 ng/mL, range 253-531 ng/mL) and healthy controls (median 319 ng/mL, range 142-430 ng/mL) showed intermediate CSF OPN levels.</s><s>Lowest CSF OPN levels were seen in MS (median 163 ng/mL, range 29-370 ng/mL) and GBM (median 41 ng/mL, range 22-191 ng/mL) patients.</s><s>The median CSF OPN level in all CNSL patients was 620 ng/mL (range 60-890 ng/mL) and thus higher than in patients with inflammatory CNS disease; P &lt; .05,</s><s>with MS; P &lt; .01,</s><s>with GBM; P &lt; .01 and healthy controls; P &lt; .01</s><s>(Figure <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>In contrast to CSF, median OPN serum levels were low and did not differ between PCNSL patients (median 52 ng/mL, range 17-231 ng/mL), patients with inflammatory CNS disease (median 99 ng/mL, range 40-273 ng/mL), and healthy controls (median 59 ng/mL, range 22-203 ng/mL); P = .158</s><s>(Figure <ref type="figure" target="#fig_2">2A</ref>).</s><s>The CSF/serum-ratio was predictably higher in PCNSL patients than in patients with inflammatory CNS disease or in healthy controls; both P &lt; .01</s><s>(Figure <ref type="figure" target="#fig_2">2B</ref>).</s></p><p><s>Steroid pre-treatment in CNSL patients did not influence CSF OPN level (P = .984).</s><s>Spearman correlation analysis indicates a significant increase of CSF OPN with age in the healthy controls (r = .663,</s><s>P = .014,</s><s>n = 13), whereas in CNSL patients we did not find such a correlation (r = -.186,</s><s>P = .269,</s><s>n = 37).</s><s>CSF OPN did not correlate with CSF cell count (r = -.050 in healthy controls and r = -.179 in CNSL).</s><s>Moreover, CSF OPN weakly correlated with total CSF protein in CNSL patients (r = .383,</s><s>P = .053),</s><s>but not in healthy controls (r = .209,</s><s>P = .494).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic value of CSF OPN</head><p><s>On the basis of ROC curves, we analysed the diagnostic value of CSF OPN as a diagnostic biomarker for CNSL (Figure <ref type="figure" target="#fig_3">3</ref> and Supplementary Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>The area under the ROC curve was .934</s><s>(95% confidence interval [CI] .873</s><s>-.995) for differentiating CNSL from all control patients (cut-off 400 ng/mL, sensitivity 87%, specificity 86%), .865</s><s>(95% CI .745</s><s>-.985) for differentiating CNSL from inflammatory CNS disease (cut-off 438 ng/mL, sensitivity 84%, specificity 83%), .956</s><s>(95% CI .898</s><s>-1.000) for differentiating CNSL from MS (cut-off 362 ng/mL, sensitivity 89%, specificity 88%), .988</s><s>(95% CI .964</s><s>-1.000) for CNSL vs. GBM patients (cut-off 240 ng/mL, sensitivity 95%, specificity 100%), and .915</s><s>(95% CI .834</s><s>-.996) for CNSL vs. healthy controls (cut-off 419 ng/mL, sensitivity 87%, specificity 85%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prognostic value of CSF OPN in patients with PCNSL</head><p><s>Survival data of 25 PCNSL patients with CSF OPN level measured at time of diagnosis were analysed.</s><s>The median follow-up was 21.4 months.</s><s>Median PFS and median OS were 26.5 months (95% CI 14.4-38.5 months) and 32.5 months (95% CI 19.2-45.7 months), respectively.</s><s>In univariate analysis, higher level of CSF OPN was significantly associated with shorter PFS (HR 1.47, 95% CI 1.02-2.10,</s><s>P = .037),</s><s>whereas the difference in OS was not significant (HR 1.28, 95% CI .89-1.84;</s><s>P = .187,</s><s>see also Supplementary Figure <ref type="figure" target="#fig_2">2</ref> with median CSF OPN as cut-off).</s><s>In multivariate analysis with clinical characteristics age and sex, CSF OPN was significantly associated with shorter PFS (HR 1.61, 95% CI 1.13-2.31,</s><s>P = .009)</s><s>and OS (HR 1.52, 95% CI 1.04-2.21;</s><s>P = .029).</s><s>Spearman correlation analysis revealed a significant correlation between CSF OPN level and multifocal brain involvement (r = .460,</s><s>P = .021).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>We provide first evidence that CSF OPN might be a valuable, easy to measure, and cost-effective diagnostic and prognostic biomarker in CNSL.</s><s>ROC analyses revealed that CSF OPN discriminated patients with CNSL from control groups with high sensitivity and specificity.</s><s>In contrast to elevated OPN in CSF, serum levels were low and comparable to those of patients with inflammatory CNS disease and healthy controls.</s><s>This indicates that in CNSL patients, high CSF OPN levels are due to production and secretion in the CNS and are not the consequence of a systemic inflammation with concomitant CNS involvement.</s></p><p><s>Due to the rarity of CNSL, very little is known about the mechanisms leading to development of this disease in CNS, which is largely devoid of lymphoid tissue.</s><s>High-levels of proinflammatory proteins such as neopterin [15] and -as described in this report -osteopontin may suggest a neuroinflammatory process.</s><s>First data on gene and protein expression in PCNSL indicate an up-regulation of genes associated with cell signalling in extracellular matrix and adhesion related pathways such as DDR1, CXCL13, MUM1, TCL1a, CHI3L1 and OPN <ref type="bibr" target="#b20">[25]</ref><ref type="bibr">[26]</ref><ref type="bibr">[27]</ref><ref type="bibr" target="#b21">[28]</ref>.</s><s>When OPN expression levels were compared between PCNSL, extranodal DLBCL, and nodal DLBCL, an expression was observed in 100% and 95% in the both first groups compared to 25% in the third group, suggesting its probable role in CNS tissue tropism <ref type="bibr" target="#b20">[25]</ref>.</s><s>Moreover, higher CSF OPN levels were found in childhood acute leukaemia with CNS involvement than in patients without CNS involvement suggesting a role of OPN as a marker of secondary CNS involvement <ref type="bibr">[19]</ref>.</s><s>Since high CSF OPN levels were detected in SCNSL patients, OPN could represent an early marker of secondary CNS involvement in systemic lymphoma.</s><s>This is worth further evaluation considering the low diagnostic value of currently known risk factors to identify patients with high risk for secondary CNS involvement in lymphoma <ref type="bibr" target="#b22">[29]</ref> and an urgent need for markers guiding CNS prophylaxis.</s></p><p><s>Numerous studies reported increased CSF OPN levels in patients with MS and other neuroinflammatory and neurodegenerative diseases <ref type="bibr" target="#b23">[30]</ref><ref type="bibr" target="#b24">[31]</ref><ref type="bibr">[32]</ref><ref type="bibr" target="#b25">[33]</ref>.</s><s>In our study, the median CSF OPN level of MS patients was in accordance with data published by others <ref type="bibr" target="#b24">[31,</ref><ref type="bibr" target="#b25">33]</ref>.</s><s>However, CSF OPN level in patients with neuroinflammatory disease, e.g.</s><s>MS, reflects the extent of inflammation and dynamically varies in correlation to activity of disease <ref type="bibr" target="#b23">[30]</ref>.</s><s>Therefore, the median CSF OPN level of our MS patients may differ to OPN levels reported by others.</s></p><p><s>For GBM, high-level OPN expression has been demonstrated by immunohistochemistry, and relatively high OPN levels in CSF of GBM patients were reported in one study <ref type="bibr" target="#b26">[34]</ref>, which is in contrast to our findings.</s><s>Methodological differences as well as differences in patients' characteristics and pre-treatment might be explanations for the difference to our GBM samples.</s><s>CSF OPN levels of our healthy controls were higher than reported by other studies of patients with childhood acute leukaemia without CNS involvement and patients with neurologic symptoms, but without confirmed neurologic disease <ref type="bibr">[19,</ref><ref type="bibr" target="#b27">35,</ref><ref type="bibr" target="#b28">36]</ref>.</s><s>Although no CNS disease was found in our healthy controls, we cannot rule out conditions, as e.g.</s><s>peripheral neuropathy, with an influence on CSF OPN levels in some of them.</s></p><p><s>In addition to the diagnostic role, OPN may represent an easy to measure prognostic marker in CNSL.</s></p><p><s>Patients with higher OPN levels had shorter PFS and OS.</s><s>Furthermore, higher CSF OPN significantly correlated with multifocal brain involvement, which indicates that OPN level reflects tumour burden in CNSL.</s><s>An association of multifocal brain involvement with inferior outcome has previously been reported <ref type="bibr" target="#b29">[37,</ref><ref type="bibr" target="#b30">38]</ref>.</s><s>Moreover, a correlation of increased circulating OPN levels and increased OPN expression by tumour cells with an unfavourable prognosis was found in other human malignancies <ref type="bibr" target="#b15">[20]</ref><ref type="bibr" target="#b16">[21]</ref><ref type="bibr">[22]</ref>.</s></p><p><s>OPN and its receptor CD44 have been identified as a promising therapeutic target for cancer therapy <ref type="bibr" target="#b31">[39,</ref><ref type="bibr" target="#b32">40]</ref>.</s><s>Considering the generally poor prognosis of CNSL, identifying new targets for more effective therapies is highly desirable in this disease.</s><s>If the contribution of OPN to CNS lymphomagenesis is confirmed, evaluation of the inhibition of OPN and/or its receptor as novel treatment strategy for CNSL will be worth evaluating.</s></p><p><s>A comprehensive overview of previously reported potential biomarkers for PCNSL diagnosis was published recently <ref type="bibr">[15]</ref>.</s><s>A combination of OPN with other biomarkers such as IL-10, CXCL13 or neopterin could improve diagnostic yield and should be tested.</s><s>The small sample size, especially of the control groups, represents a major limitation of our study.</s><s>Further studies with larger control groups are needed to validate our results.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>CSF OPN levels in CNSL and control patients.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure legend :</head><label>legend</label><figDesc><div><p><s>Figure legend: Black lines indicate median OPN levels.</s><s>P values were adjusted by</s></p></div></figDesc><graphic coords="15,71.30,107.95,235.55,220.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. A) CSF and serum OPN levels in PCNSL and control patients, B) CSF/serum-ratio in PCNSL and control patients.A) B)</s></p></div></figDesc><graphic coords="16,321.85,118.15,227.05,259.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. ROC curve analyses of CSF OPN levels.</s></p></div></figDesc><graphic coords="17,70.85,92.50,359.55,375.85" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure legend :</head><label>legend</label><figDesc><div><p><s>Figure legend: ROC…receiver operating characteristic, CSF...cerebrospinal fluid,</s></p></div></figDesc></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Deckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Engert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bruck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ferreri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Finke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Illerhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kuppers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maarouf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montesinos-Rongen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Paulus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lassmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">D</forename><surname>Wiestler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Deangelis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1797" to="1807" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin&apos;s Lymphoma Study Group (DSHNHL)</title>
		<author>
			<persName><forename type="first">V</forename><surname>Boehme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zeynalova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kloess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schmitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="149" to="157" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Diagnosis and treatment of primary CNS lymphoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="317" to="327" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system</title>
		<author>
			<persName><forename type="first">A</forename><surname>Baraniskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schulte-Altedorneburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schroers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="421" to="432" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology</title>
		<author>
			<persName><forename type="first">R</forename><surname>Schroers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baraniskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heute</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vorgerd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuhnhenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kowoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alekseyev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schmiegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="520" to="528" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gleissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Siehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Reinhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="390" to="396" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Bromberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Doorduijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Illerhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jahnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fritsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kuittinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Issa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Van Montfort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Van Den Bent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="808" to="813" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Klasen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roeth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hertenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hundsberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leithauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Birnbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kirchen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Mergenthaler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Berdel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Birkmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fischer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="2374" to="2380" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system</title>
		<author>
			<persName><forename type="first">A</forename><surname>Baraniskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuhnhenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maghnouj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zollner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reinacher-Schick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schmiegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schroers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="3140" to="3146" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Hoheisel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Codo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Backes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Leidinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baraniskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuhnhenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schmiegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schroers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nakamizo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kawamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mizukawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="239" to="244" />
			<date type="published" when="2012">2015 11. 2012</date>
		</imprint>
	</monogr>
	<note>J Neurooncol</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Miyake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Taniguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hosoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kohmura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="368" to="380" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">CXCL13 and CXCL12 in central nervous system lymphoma patients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pfeiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kiewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Volk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cakiroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Widmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="5968" to="5973" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Rubenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kadoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barajas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Josephson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Douglas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Treseler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cinque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cyster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Viaccoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ducray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tholance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Barcelos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thomas-Maisonneuve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ghesquieres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Meyronet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Quadrio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cartalat-Carel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Louis-Tisserand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jouanneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guyotat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Honnorat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Perret-Liaudet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol</title>
				<imprint>
			<date type="published" when="2013">2013. 2015</date>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="4740" to="4748" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Brown A: Osteopontin: A Key Link between Immunity, Inflammation and the Central Nervous System</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Shevde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Samant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Neurosci</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="288" to="293" />
			<date type="published" when="2012">2014. 2012</date>
		</imprint>
	</monogr>
	<note>Matrix Biol</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The relationship between cerebrospinal fluid osteopontin level and central nervous system involvement in childhood acute leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Cheon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Incesoy-Ozdemir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bozkurt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Oren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Balkaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Ertem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tuberc Respir Dis (Seoul)</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="42" to="49" />
			<date type="published" when="2013">2013 19. 2013</date>
		</imprint>
	</monogr>
	<note>Turk J Pediatr</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Osteopontin is a prognostic biomarker in non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Rud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Oijordsbakken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lund-Iversen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Halvorsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Solberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Berge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Helland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Brustugun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Maelandsmo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Poruk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Firpo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Scaife</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Mulvihill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="193" to="197" />
			<date>2013 22</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Lu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1429" to="1434" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">F</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Lou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">H</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Z</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">X</forename><surname>Qin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="929" to="937" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Enomoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurooncol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="343" to="351" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Tun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Personett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Baskerville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Menke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Jaeckle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kreinest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Edenfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Zubair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>O'neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mckinney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>; Rubenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Batchelor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kadoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Treseler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Shuman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="266" to="267" />
			<date type="published" when="2009">2013 26. 2008 27. 2009</date>
		</imprint>
	</monogr>
	<note>Blood. author reply 267-268</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Selective central nervous system tropism of primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Marlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Roemeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Menke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Copland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Tun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Pathol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="763" to="767" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Central nervous system involvement following diagnosis of non-Hodgkin&apos;s lymphoma: a risk model</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hollender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kvaloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Nome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Skovlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1099" to="1107" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Sadiq</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="232" to="235" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Braitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nunan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Niepel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Constantinescu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">244</biblScope>
			<biblScope unit="page" from="633" to="635" />
			<date type="published" when="2008">2012. 2008</date>
		</imprint>
	</monogr>
	<note>Arch Neurol</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bornsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Khademi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Sorensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sellebjerg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mult Scler</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="32" to="42" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Myles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merchant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Harsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Glantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Recht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Morser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Leung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="3097" to="3111" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sharrack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ismail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Tench</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dhungana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brettschneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tumani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Constantinescu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="234" to="244" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity</title>
		<author>
			<persName><forename type="first">L</forename><surname>Szalardy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zadori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bencsik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vecsei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Klivenyi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">331</biblScope>
			<biblScope unit="page" from="38" to="42" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Surgery for primary CNS lymphoma? Challenging a paradigm</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1481" to="1484" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Primary non-Hodgkin&apos;s lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Bessell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Graus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Punt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Firth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Hope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Moloney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Guillermo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Villa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="945" to="954" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immunol Immunother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="355" to="366" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Zoller M: CD44v10, osteopontin and lymphoma growth retardation by a CD44v10-specific antibody</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Megaptche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Erb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Buchler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="709" to="720" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
